BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$82.33 USD
-1.17 (-1.40%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $82.35 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BMRN 82.33 -1.17(-1.40%)
Will BMRN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BMRN
Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
BioMarin (BMRN) Down 7.6% Since Last Earnings Report: Can It Rebound?
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
Other News for BMRN
Cracking The Code: Understanding Analyst Reviews For Biomarin Pharmaceutical
Wall Street Analysts Are Bullish on Top Healthcare Picks
BioMarin price target raised by $4 at Wells Fargo, here's why
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT) and Alnylam Pharma (ALNY)
BioMarin to Present Data Highlighting Significant Impact of VOXZOGO® (vosoritide) in Bone Health and Health-Related Quality of Life in Achondroplasia at 2024 International Conference on Children's Bone Health